Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Muhammad Ary Zucha, Alexander T H Wu, Wei Hwa Lee, Liang Shun Wang, Wan Wan Lin, Chiou Chung Yuan, Chi-Tai Yeh

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

Original languageEnglish
Pages (from-to)13255-13268
Number of pages14
JournalOncotarget
Volume6
Issue number15
Publication statusPublished - 2015

Fingerprint

Ovarian Neoplasms
Cisplatin
Neoplastic Stem Cells
Up-Regulation
Databases
Survival
Genes
PCI 32765
Agammaglobulinaemia tyrosine kinase

Keywords

  • Bruton's tyrosine kinase (Btk)
  • Cancer stem cell (CSC)
  • Cisplatin
  • Ibrutinib
  • Ovarian cancer
  • Spheroids

ASJC Scopus subject areas

  • Oncology

Cite this

Zucha, M. A., Wu, A. T. H., Lee, W. H., Wang, L. S., Lin, W. W., Yuan, C. C., & Yeh, C-T. (2015). Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget, 6(15), 13255-13268.

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. / Zucha, Muhammad Ary; Wu, Alexander T H; Lee, Wei Hwa; Wang, Liang Shun; Lin, Wan Wan; Yuan, Chiou Chung; Yeh, Chi-Tai.

In: Oncotarget, Vol. 6, No. 15, 2015, p. 13255-13268.

Research output: Contribution to journalArticle

Zucha, MA, Wu, ATH, Lee, WH, Wang, LS, Lin, WW, Yuan, CC & Yeh, C-T 2015, 'Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer', Oncotarget, vol. 6, no. 15, pp. 13255-13268.
Zucha, Muhammad Ary ; Wu, Alexander T H ; Lee, Wei Hwa ; Wang, Liang Shun ; Lin, Wan Wan ; Yuan, Chiou Chung ; Yeh, Chi-Tai. / Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. In: Oncotarget. 2015 ; Vol. 6, No. 15. pp. 13255-13268.
@article{bcb1182d0a184149b2195fcb2ac21554,
title = "Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer",
abstract = "According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.",
keywords = "Bruton's tyrosine kinase (Btk), Cancer stem cell (CSC), Cisplatin, Ibrutinib, Ovarian cancer, Spheroids",
author = "Zucha, {Muhammad Ary} and Wu, {Alexander T H} and Lee, {Wei Hwa} and Wang, {Liang Shun} and Lin, {Wan Wan} and Yuan, {Chiou Chung} and Chi-Tai Yeh",
year = "2015",
language = "English",
volume = "6",
pages = "13255--13268",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "15",

}

TY - JOUR

T1 - Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

AU - Zucha, Muhammad Ary

AU - Wu, Alexander T H

AU - Lee, Wei Hwa

AU - Wang, Liang Shun

AU - Lin, Wan Wan

AU - Yuan, Chiou Chung

AU - Yeh, Chi-Tai

PY - 2015

Y1 - 2015

N2 - According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

AB - According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

KW - Bruton's tyrosine kinase (Btk)

KW - Cancer stem cell (CSC)

KW - Cisplatin

KW - Ibrutinib

KW - Ovarian cancer

KW - Spheroids

UR - http://www.scopus.com/inward/record.url?scp=84931092005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931092005&partnerID=8YFLogxK

M3 - Article

C2 - 26036311

AN - SCOPUS:84931092005

VL - 6

SP - 13255

EP - 13268

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 15

ER -